BioSpace News Archive

Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, announced an agreement with India-based Spinco Biotech to further extend its reach in Asia.

Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical company developing a first-in-class small molecule ChemR23 agonist to treat cancer and autoimmune diseases small molecule (TP-317) to treat cancer and autoimmune diseases

GT Medical Technologies, Inc., a medical device company dedicated to improving the lives of patients with brain tumors, announced that Ty Atteberry has joined the company as Vice President of Sales.

Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (“Defence” or the “Company”), a Canadian biopharmaceutical company developing cutting-edge vaccines, therapeutics, and drug delivery technologies against cancer and other diseases

Mnemo Therapeutics, a biotechnology company developing transformational immunotherapies, has announced a new preclinical study showing that CAR T cell memory differentiation and persistence can be enhanced by inactivating SUV39H1, an enzyme (histone methyltransferase) that epigenetically regulates and represses memory-associated genes.

PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLD) (“PharmaDrug” or the “Company”), is pleased to announce that it has closed the previously announced acquisition (see press release dated October 27, 2023) of Securedose Synthetics Inc. (“SecureDose”)

Mitsubishi Tanabe Pharma Canada, a subsidiary of Mitsubishi Tanabe Pharma America, Inc., announced that RADICAVA® Oral Suspension is now covered under the Prince Edward Island Pharmacare Formulary and the Newfoundland and Labrador Prescription Drug Program for the treatment of people living with amyotrophic lateral sclerosis, a rapidly progressive, neurodegenerative disease.

MedGenome, a global precision medicine company specializing in omics solutions, announced that it has achieved the 10x Genomics Certified Service Provider qualification for its single cell offering.

ZKR Orthopedics, Inc. a clinical stage medical device company, announced successful completion of two-year follow up on subjects enrolled in the first-in-human clinical trial.

LAPIX Therapeutics, Inc. today announced that the first participants have been dosed in the Phase 1 study of the Company’s LPX-TI641therapy.